全文获取类型
收费全文 | 4315篇 |
免费 | 259篇 |
国内免费 | 94篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 135篇 |
妇产科学 | 87篇 |
基础医学 | 764篇 |
口腔科学 | 99篇 |
临床医学 | 288篇 |
内科学 | 356篇 |
皮肤病学 | 574篇 |
神经病学 | 317篇 |
特种医学 | 59篇 |
外科学 | 140篇 |
综合类 | 541篇 |
预防医学 | 204篇 |
眼科学 | 339篇 |
药学 | 365篇 |
1篇 | |
中国医学 | 250篇 |
肿瘤学 | 119篇 |
出版年
2023年 | 50篇 |
2022年 | 102篇 |
2021年 | 159篇 |
2020年 | 108篇 |
2019年 | 115篇 |
2018年 | 110篇 |
2017年 | 124篇 |
2016年 | 139篇 |
2015年 | 95篇 |
2014年 | 194篇 |
2013年 | 243篇 |
2012年 | 220篇 |
2011年 | 232篇 |
2010年 | 198篇 |
2009年 | 162篇 |
2008年 | 199篇 |
2007年 | 170篇 |
2006年 | 196篇 |
2005年 | 165篇 |
2004年 | 161篇 |
2003年 | 150篇 |
2002年 | 116篇 |
2001年 | 120篇 |
2000年 | 103篇 |
1999年 | 95篇 |
1998年 | 62篇 |
1997年 | 88篇 |
1996年 | 69篇 |
1995年 | 65篇 |
1994年 | 66篇 |
1993年 | 43篇 |
1992年 | 53篇 |
1991年 | 44篇 |
1990年 | 34篇 |
1989年 | 44篇 |
1988年 | 31篇 |
1987年 | 32篇 |
1986年 | 29篇 |
1985年 | 61篇 |
1984年 | 42篇 |
1983年 | 31篇 |
1982年 | 47篇 |
1981年 | 25篇 |
1980年 | 13篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 20篇 |
1972年 | 4篇 |
1969年 | 3篇 |
排序方式: 共有4668条查询结果,搜索用时 15 毫秒
1.
Sarah E. Sheppard Laura Elizabeth Anderson Cathryn Sibbald Colleen Cotton Elizabeth Bhoj Marissa J. Perman Leslie Castelo‐Soccio 《Pediatric dermatology》2019,36(6):1007-1009
Epidermolysis bullosa simplex (EBS) is a skin fragility disorder resulting from mutations of structural proteins in the epidermis. We provide a brief report of long‐term survival and reproduction in a mother with EBS due to keratin 5 (KRT5) c.1429G > A (p.E477K) mutation, which causes a particularly severe form of the disease. 相似文献
2.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献3.
《Vaccine》2016,34(26):2948-2952
Herpes simplex virus type-1 (HSV-1) and -2 (HSV-2) are highly prevalent global pathogens which commonly cause recurrent oral and genital ulcerations. Less common but more serious complications include meningitis, encephalitis, neonatal infection, and keratitis. HSV-2 infection is a significant driver of the HIV epidemic, increasing the risk of HIV acquisition 3 fold. As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development. We will provide an overview of efforts to develop HSV-2 vaccines, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing. In addition, we will touch upon aspects of HSV vaccine development relevant to low and middle income countries. 相似文献
4.
Jusleen Ahluwalia Allison Han Ayan Kusari Lawrence F. Eichenfield 《Pediatric dermatology》2019,36(6):808-814
Recurrent herpes labialis (RHL) is an incredibly common condition, though the medical literature evaluating pediatric aspects is limited. This paper assesses prevalence and therapeutic studies of pediatric RHL as well as disease complications. A comprehensive literature search of English‐language citations based on PubMed queries of selected terms was performed, with exclusion if methodology was not discussed, or if studies had 10 or fewer patients. RHL prevalence in pediatrics has been assessed by measures of point and periodic prevalence, though methodologic limitations may under‐ or over‐estimate the true prevalence of RHL. Studies have been conducted to evaluate therapeutic safety, tolerability, and efficacy of antivirals in the pediatric population. Pediatric RHL point prevalence ranges from 0.72% to 5.2% depending on the population study and the methodologies used. Pediatric RHL carries a significant public health burden and is often implicated in patients with eczema herpeticum, erythema multiforme, reactive infectious mucositis eruptions, and hypersensitivity reactions. There are few studies that evaluate the rates of occurrence of these sequelae associated with pediatric RHL. 相似文献
5.
Dermoscopic features of hidroacanthoma simplex: Usefulness in distinguishing it from Bowen's disease and seborrheic keratosis
下载免费PDF全文
![点击此处可从《The Journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Chihiro Shiiya Hiroo Hata Yuka Inamura Keisuke Imafuku Shinya Kitamura Hiromi Fujita Hiroshi Shimizu 《The Journal of dermatology》2015,42(10):1002-1005
Hidroacanthoma simplex (HAS) is a rare benign eccrine adnexal tumor. HAS is sometimes clinically or pathologically misdiagnosed as squamous cell carcinoma in situ (Bowen's disease; BD), seborrheic keratosis (SK) or other adnexal tumor. To date, there has never been a report focusing on dermoscopic features to distinguish HAS from BD and SK. We found the following dermoscopic findings to be characteristic of HAS: fine black dots/globules (75% of cases) and fine scales arranged annularly (100% of cases). In contrast, glomerular vessels, which are typically observed in BD, were not seen in any of the four cases. Cerebriform appearance and milia‐like cysts, which are typically observed in SK, were also not seen in any of the four cases. The existence of “scattered fine black dots/globules” and “fine scales arranged annularly”, and the absence of the glomerular vessels, may contribute to precise diagnosis of HAS. Even though HAS resembles BD or SK clinically, it can be distinguished from these by the characteristic dermoscopic features. 相似文献
6.
目的:检测诱导型和内皮型一氧化氮合酶(iNOS 和eNOS)在外阴慢性单纯性苔藓和外阴硬化性苔藓中的表达。方法:采用免疫组织化学SABC法检测iNOS和eNOS在30例外阴慢性单纯性苔藓蜡块(LSC)、30例外阴硬化性苔藓蜡块(LS)和10例外阴正常皮肤中的表达,并以人原始造血细胞抗原(CD34)标记微血管内皮细胞,测量各组织的微血管密度(MVD)。结果:iNOS和eNOS在外阴正常皮肤中无表达;在LSC中iNOS和eNOS每视野平均阳性细胞数分别为14.83±3.79和17.86±4.82,高于LS的8.00±3.35和6.43±3.87,差异均有统计学意义(P<0.05);在LSC和正常皮肤中MVD分别为21.58±2.48和20.44±3.66,高于LS(10.34±2.83)。iNOS和eNOS的表达具有明显的正相关性(Kappa=0.811,P<0.05)。结论:iNOS和eNOS可能与LSC炎症过程中的血管扩张有关;在LS皮损真皮中微血管减少,iNOS和eNOS可代偿性地改善LS的血液循环。 相似文献
7.
腺病毒介导的HSV—tk基因治疗大鼠脑胶质瘤实验研究 总被引:4,自引:0,他引:4
目的:带有HSV-tk基因的重组腺病毒(AdHCMV-tk)结合核苷类似物(NA)治疗大鼠C6脑胶质瘤。方法:用X-gal染色测定AdHCMV-lacZ转染大鼠C6胶质瘤细胞的效率。用AdHCMV-tk/ACV、GCV离体及活体治疗大鼠C6胶质瘤。结果:AdHCMV-lacZ感染C6细胞效率达100%,AdHCMV-tk感染C6细胞,在病毒感染复数为1000时,GCV和ACV半致死剂量分别为3μg/ml和20μg/ml,Ad-HCMV-tk/ACV治疗大鼠C6胶质瘤模型,大鼠生存期超过90天,而对照组分别为17.0±1.6天(生理盐水组)、14.5±1.3天(AdHCMV-lacZ组),P<0.001。结论:重组腺病毒对靶细胞感染效率可达100%,AdHCMV-tk用GCV的杀伤C6胶质瘤细胞比ACV强,而HSV-tk/ACV用腺病毒介导治疗大鼠脑肿瘤疗效显著。 相似文献
8.
Permissive herpes simplex virus (HSV) infection in tissue culture results in host cell destruction. Latent HSV infection in vivo occurs in neurons of peripheral sensory ganglia (PSG) and it therefore can not take place in neurons in which the virus has completed a lytic replication cycle similar to that present in vitro. Our hypothesis, based on experimental data and observations in humans, suggests that establishment of latent infection and reactivation of HSV-1 does not involve neuronal cell loss. Latency is established in neurons in which the virus does not replicate and is determined, in part, by the tissue levels of a herpes transactivating protein (Vmw65) that is a component of the viral tegument. We also suggest that reactivation of latent infection does not involve destruction of neurons and is due to replication of virus at the peripheral mucocutaneous tissues to where virus or viral DNA have been transported from the nervous tissue. Alternatively, reactivation is initiated in the PSG using a replication cycle which does not involve irreversible damage to neurons. This model explains the lack of damage to neurons which continue to serve as permanent reservoirs of latent virus for the entire life of the host. 相似文献
9.
单纯疱疹病毒感染与冠心病急性心肌梗死血液流变特性的相关性研究 总被引:2,自引:1,他引:1
目的 探讨单纯疱疹病毒 (HSV)感染与冠心病心肌梗死的关系。方法 测定 5 1例急性心肌梗死 (AMI)和 4 2例陈旧性心肌梗死 (OMI)患者及 31例冠脉造影正常者 (NC)的HSV - 1特异性抗体 (HSV - 1IgG、HSV - 1IgM)浓度 ,并同步观察纤维蛋白原 (Fg)、血液流变特性指标变化及其与HSV - 1感染的相关性。结果 AMI组HSV - 1IgG阳性率及平均浓度明显高于NC组 (P <0 0 5 ) ,HSV - 1DNA检测结果与之吻合。校正冠心病危险因素前后HSV - 1IgG阳性与AMI均有相关关系 (OR4 2 6 6 ,P =0 0 19;OR 3 82 1,P =0 0 32 )。AMI组IgG、Fg、血浆黏度、低 /高切全血黏度、红细胞压积、红细胞聚集指数高于 ,而红细胞变形指数低于NC组及OMI组 (P均 <0 0 5 )。AMI组中HSV - 1( )组上述指标 (除HCT外 )的改变与同组中HSV - 1( - )组及与NC、OMI组中HSV - 1( )组比较有显著性差异 (P均 <0 0 5 ) ,AMI组中HSV - 1( )组IgG与Fg、血浆黏度、低 /高切全血黏度、红细胞聚集指数呈正相关 ,而与红细胞变形指数呈负相关 ,调整冠心病的危险因素前后IgG与Fg均呈正相关。结论 HSV - 1感染与CHD(AMI)之间存在明显的相关性 ,与Fg、血液流变特性指标也存在相关性。 相似文献
10.
不同剂量和疗程伐昔洛韦治疗带状疱疹的多中心随机双盲对照研究 总被引:1,自引:0,他引:1
目的:比较不同剂量和疗程伐昔洛韦治疗带状疱疹的疗效和安全性。方法:选择带状疱疹患者为研究对象,采用多中心、随机、双盲、对照的临床试验。试验组患者采用伐昔洛韦1000mg每日3次口服,共服7d;对照组患者采用伐昔洛韦300mg每日2次口服,共服10d。用药后第3、6和10天观察疗效和不良反应。结果:共入组128例,全分析集(FAS)分析128例,符合方案集(PPS)分析118例。治疗后第3、6和10天,试验组和对照组患者的症状、体征积分下降值及有效率比较差异无统计学意义(P〉0.05);疼痛视觉模拟评分法(visnal analogue scale,VAS)值比较,两组间差异无统计学意义(P〉0.05),但入组时疼痛VAS值≥8的患者,FAS集分析显示,在治疗后第6、10天VAS值下降两组均存在统计学差异(P〈0.05);PPS集分析显示治疗后第10天VAS值下降,两组间存在统计学差异俨〈0.05)。试验组和对照组不良反应发生率分别为17.18%和12.50%.主要为嗜睡和恶心。结论:增加伐昔洛韦用量治疗带状疱疹安全、有效,与较低剂量伐昔洛韦组相比,对疼痛程度较严重的患者能更显著地减轻疼痛。 相似文献